Interaction between adenosine and angiotensin II in renal microcirculation. 1991

M S Dietrich, and K Endlich, and N Parekh, and M Steinhausen
First Institute of Physiology, University of Heidelberg, Federal Republic of Germany.

In order to examine the possibility of an interaction between adenosine and angiotensin II (A II) in the control of the renal microcirculation, we studied the effects of agonists and antagonists of both substances by means of in vivo microscopy in the split hydronephrotic rat kidney. In a first series of experiments (n = 6), local application of the A II receptor antagonist saralasin (10(-6) mol.liter-1 abolished the vasoconstriction and the reduction of glomerular blood flow induced by the A1-adenosine receptor agonist N6-cyclohexyladenosine (CHA, local concentration 10(-7) mol.liter-1). Without saralasin (second series, n = 6), CHA reduced glomerular blood flow and decreased vessel diameters as previously reported from our laboratory. In a third series of experiments (n = 6), A II significantly reduced vessel diameters and glomerular blood flow both alone and during blockage of the A1-adenosine receptor by the selective antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, 10(-5) mol.liter-1). In additional experiments, we excluded nonspecific receptor effects of saralasin and confirmed the inhibitory action of DPCPX on the adenosine-induced vasoconstriction. We suppose that adenosine needs a functioning A II receptor system for its vasoconstrictor action, whereas A II can induce a nonadenosine-dependent vasoconstriction.

UI MeSH Term Description Entries
D007678 Kidney Glomerulus A cluster of convoluted capillaries beginning at each nephric tubule in the kidney and held together by connective tissue. Glomerulus, Kidney
D008833 Microcirculation The circulation of the BLOOD through the MICROVASCULAR NETWORK. Microvascular Blood Flow,Microvascular Circulation,Blood Flow, Microvascular,Circulation, Microvascular,Flow, Microvascular Blood,Microvascular Blood Flows,Microvascular Circulations
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D011945 Receptors, Angiotensin Cell surface proteins that bind ANGIOTENSINS and trigger intracellular changes influencing the behavior of cells. Angiotensin Receptor,Angiotensin Receptors,Angiotensin II Receptor,Angiotensin III Receptor,Receptor, Angiotensin II,Receptor, Angiotensin III,Receptor, Angiotensin
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females
D000241 Adenosine A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. Adenocard,Adenoscan
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012504 Saralasin An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION. 1-Sar-8-Ala Angiotensin II,1-Sarcosine-8-Alanine Angiotensin II,(Sar(1),Ala(8))ANGII,(Sar1,Val5,Ala8)Angiotensin II,Angiotensin II, Sar(1)-Ala(8)-,Angiotensin II, Sarcosyl(1)-Alanine(8)-,Sar-Arg-Val-Tyr-Val-His-Pro-Ala,Saralasin Acetate,Saralasin Acetate, Anhydrous,Saralasin Acetate, Hydrated,1 Sar 8 Ala Angiotensin II,1 Sarcosine 8 Alanine Angiotensin II,Angiotensin II, 1-Sar-8-Ala,Angiotensin II, 1-Sarcosine-8-Alanine,Anhydrous Saralasin Acetate,Hydrated Saralasin Acetate

Related Publications

M S Dietrich, and K Endlich, and N Parekh, and M Steinhausen
June 1998, Hypertension (Dallas, Tex. : 1979),
M S Dietrich, and K Endlich, and N Parekh, and M Steinhausen
May 2000, Journal of cardiovascular pharmacology,
M S Dietrich, and K Endlich, and N Parekh, and M Steinhausen
December 1979, The American journal of physiology,
M S Dietrich, and K Endlich, and N Parekh, and M Steinhausen
July 1999, Clinical and experimental pharmacology & physiology,
M S Dietrich, and K Endlich, and N Parekh, and M Steinhausen
March 1993, The Journal of pharmacology and experimental therapeutics,
M S Dietrich, and K Endlich, and N Parekh, and M Steinhausen
February 1990, The American journal of physiology,
M S Dietrich, and K Endlich, and N Parekh, and M Steinhausen
January 2009, Current opinion in nephrology and hypertension,
M S Dietrich, and K Endlich, and N Parekh, and M Steinhausen
April 1987, Clinical science (London, England : 1979),
M S Dietrich, and K Endlich, and N Parekh, and M Steinhausen
May 2021, Acta physiologica (Oxford, England),
M S Dietrich, and K Endlich, and N Parekh, and M Steinhausen
March 1985, The American journal of physiology,
Copied contents to your clipboard!